← Back to Search

Monoclonal Antibodies

Nivatrotamab for Small Cell Lung Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Y-mAbs Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose until 30 days after last imp, up to 26 weeks. actual duration for treated patients were from 21 to 58 days.
Awards & highlights

Study Summary

This study is evaluating whether a monoclonal antibody can be safely given to people with small cell lung cancer.

Eligible Conditions
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose until 30 days after last imp, up to 26 weeks. actual duration for treated patients were from 21 to 58 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose until 30 days after last imp, up to 26 weeks. actual duration for treated patients were from 21 to 58 days. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Limiting Toxicities (DLTs) Phase I
Number of Participants With Adverse Events (AEs) for Different Doses of Nivatrotamab in Phase I

Trial Design

1Treatment groups
Experimental Treatment
Group I: NivatrotamabExperimental Treatment1 Intervention
Subcutaneous administration of nivatrotamab up to 13 cycles

Find a Location

Who is running the clinical trial?

Y-mAbs TherapeuticsLead Sponsor
25 Previous Clinical Trials
1,554 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
2021. "Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04750239.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top